Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.

Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, Grégoire M, Porte H, Copin MC, Lassalle P.

Clin Cancer Res. 2007 May 15;13(10):2928-35.

2.

[New diagnostic markers for malignant pleural mesothelioma].

Grigoriu BD, Grégoire M, Chahine B, Scherpereel A.

Bull Cancer. 2008 Feb;95(2):177-84. doi: 10.1684/bdc.2008.0576. Review. French.

3.

Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma.

Pantazopoulos I, Boura P, Xanthos T, Syrigos K.

Eur Respir J. 2013 Mar;41(3):706-15. doi: 10.1183/09031936.00226111. Epub 2012 Jul 26. Review.

4.

Biomarkers for malignant pleural mesothelioma: current status.

Greillier L, Baas P, Welch JJ, Hasan B, Passioukov A.

Mol Diagn Ther. 2008;12(6):375-90. doi: 10.2165/1250444-200812060-00004. Review.

PMID:
19035624
5.

Molecular tumor markers for asbestos-related mesothelioma: serum diagnostic markers.

Maeda M, Hino O.

Pathol Int. 2006 Nov;56(11):649-54. Review.

PMID:
17040286
6.

Serum and pleural fluid biomarkers for mesothelioma.

Creaney J, Robinson BW.

Curr Opin Pulm Med. 2009 Jul;15(4):366-70. doi: 10.1097/MCP.0b013e32832b98eb. Review.

PMID:
19417672
7.

Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis.

Luo L, Shi HZ, Liang QL, Jiang J, Qin SM, Deng JM.

Respir Med. 2010 Jan;104(1):149-56. doi: 10.1016/j.rmed.2009.05.017. Epub 2009 Nov 30. Review.

8.

Update on malignant pleural mesothelioma.

Campbell NP, Kindler HL.

Semin Respir Crit Care Med. 2011 Feb;32(1):102-10. doi: 10.1055/s-0031-1272874. Epub 2011 Apr 15. Review.

PMID:
21500129
9.

Blood tests for asbestos-related mesothelioma.

Maeda M, Hino O.

Oncology. 2006;71(1-2):26-31. Epub 2007 Mar 5. Review.

PMID:
17344668
10.

Biomarkers for mesothelioma.

Scherpereel A, Lee YC.

Curr Opin Pulm Med. 2007 Jul;13(4):339-443. Review.

PMID:
17534183
11.

Soluble markers for diagnosis of malignant pleural mesothelioma.

Cristaudo A, Bonotti A, Simonini S, Bruno R, Foddis R.

Biomark Med. 2011 Apr;5(2):261-73. doi: 10.2217/bmm.11.18. Review.

PMID:
21473730
12.

Clinical utility of diagnostic markers for malignant pleural mesothelioma.

Grigoriu BD, Grigoriu C, Chahine B, Gey T, Scherpereel A.

Monaldi Arch Chest Dis. 2009 Mar;71(1):31-8. Review. Erratum in: Monaldi Arch Chest Dis. 2009 Jun;71(2):88.

PMID:
19522163
13.

Pleural biopsy: a reliable method for determining the diagnosis but not subtype in mesothelioma.

Bueno R, Reblando J, Glickman J, Jaklitsch MT, Lukanich JM, Sugarbaker DJ.

Ann Thorac Surg. 2004 Nov;78(5):1774-6. Review.

PMID:
15511473
14.

Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.

Hollevoet K, Reitsma JB, Creaney J, Grigoriu BD, Robinson BW, Scherpereel A, Cristaudo A, Pass HI, Nackaerts K, Rodríguez Portal JA, Schneider J, Muley T, Di Serio F, Baas P, Tomasetti M, Rai AJ, van Meerbeeck JP.

J Clin Oncol. 2012 May 1;30(13):1541-9. doi: 10.1200/JCO.2011.39.6671. Epub 2012 Mar 12. Review.

15.

[Diagnosis and staging of malignant pleural mesothelioma].

Sohrab S, Konietzko N.

Pneumologie. 2002 Jun;56(6):382-7. Review. German.

PMID:
12063622
16.

Current status of screening for malignant pleural mesothelioma.

Pass HI, Carbone M.

Semin Thorac Cardiovasc Surg. 2009 Summer;21(2):97-104. doi: 10.1053/j.semtcvs.2009.06.007. Review.

PMID:
19822280
17.

Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin-related protein.

Creaney J, Robinson BW.

Hematol Oncol Clin North Am. 2005 Dec;19(6):1025-40, v. Review.

PMID:
16325121
18.

[Malignant pleural mesothelioma: diagnosis and treatment].

Delourme J, Dhalluin X, Cortot AB, Lafitte JJ, Scherpereel A.

Rev Pneumol Clin. 2013 Feb;69(1):26-35. doi: 10.1016/j.pneumo.2012.12.003. Epub 2013 Jan 14. Review. French.

PMID:
23333048
19.

What is the best way to diagnose and stage malignant pleural mesothelioma?

Zahid I, Sharif S, Routledge T, Scarci M.

Interact Cardiovasc Thorac Surg. 2011 Feb;12(2):254-9. doi: 10.1510/icvts.2010.255893. Epub 2010 Nov 1. Review.

PMID:
21044972
20.

The established and future biomarkers of malignant pleural mesothelioma.

Panou V, Vyberg M, Weinreich UM, Meristoudis C, Falkmer UG, Røe OD.

Cancer Treat Rev. 2015 Jun;41(6):486-95. doi: 10.1016/j.ctrv.2015.05.001. Epub 2015 May 8. Review.

PMID:
25979846

Supplemental Content

Support Center